What You Should Know:
– Qure.ai, a prominent global innovator in healthcare AI, has successfully closed a $65M in Series D funding round led by Lightspeed and 360 ONE Asset, with contributions from Merck Global Health Innovation Fund and Kae Capital. The round also included participation from existing investors, including Novo Holdings, HealthQuad, and TeamFund.
– This substantial investment will accelerate the company’s expansion into the US market and other regions, boost investments in foundational AI models, and facilitate strategic acquisitions in the med-tech space.
Mission to Make Healthcare More Accessible
Founded in 2016, Qure.ai is dedicated to making healthcare more accessible and equitable across the globe. The company has developed AI solutions that have positioned it as the world’s most deployed healthcare AI, with applications in over 90 countries and 3000+ sites. Qure.ai’s technology powers the efficient identification and management of critical diseases.
Regulatory Compliance and Global Presence
Qure.ai’s products have received 18 FDA-cleared indications and are Class IIb certified per EU MDR regulations, ensuring the highest standards of safety and efficacy. The company is headquartered in Mumbai, with regional offices in New York, London, and Dubai, reflecting its global reach and commitment to making healthcare AI accessible worldwide.
Future Expansion to Strategic Markets
With this new funding, Qure.ai will focus on expanding its presence in the US and other strategic markets. The company will also invest in developing foundational AI models that can be applied across various healthcare domains. Additionally, Qure.ai plans to pursue acquisitions of complementary med-tech companies to further enhance its product portfolio and capabilities.
“Qure.ai has become a trusted medical imaging AI partner to hospitals and healthcare organizations around the world. Our work is helping to unlock clinical efficiencies and drive up the standard of care delivered to patients in the focus areas of TB, Lung Cancer and Stroke,” said Prashant Warier, Co-founder and CEO of Qure.ai. “AI helps to overcome healthcare bottlenecks, from imaging reporting backlogs and low screening uptakes to workforce resource constraints, not just in western societies like the US and Europe, but in developing nations too. We also collaborate with half of the top 20 Pharma and MedTech companies including AstraZeneca, Medtronic, and J&J, to accelerate early diagnosis and timely treatment of diseases. This Series D round is an exciting step forward in our journey and will propel us forward in our mission to reach a billion patients through our solutions.”